在动脉静脉形形中体质RIT1缺陷过度活跃RAS-MAPK信号,易受MEK抑制的影响
Friedrich G Kapp1, Farhad Bazgir2, Nagi Mahammadzade3
1Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, VASCERN VASCA European Reference Centre, 79106, Freiburg, Germany. friedrich.kapp@uniklinik-freiburg.de.
Angiogenesis
|July 5, 2024
概括
研究人员在动脉静脉瘤 (AVM) 中发现了新的RIT1基因变异. 用特拉美丁尼布等MEK抑制剂向RAS-MAPK通路显示有望减少AVM出血和大小.
科学领域:
- 血管生物学 血管生物学
- 遗传学 遗传学 是一个
- 分子医学是分子医学.
背景情况:
- 动脉静脉形 (AVM) 是导致疼痛和出血的血管异常.
- 在RAS-MAPK通路中的马赛克变异与AVM病原发生有关.
- 在AVM患者的一个子集中,因果变异仍然未被确定.
研究的目的:
- 为了调查AVM的新型遗传原因.
- 探索RIT1变种在AVM形成和信号传递中的作用.
- 评估MEK抑制在AVM中的治疗潜力.
主要方法:
- 病变的AVM组织的超深度测序.
- 在HEK293T细胞中RIT1变异的功能特征.
- 使用斑马鱼胚胎进行AVM的体内建模.
- 药理上抑制MEK信号传递.
主要成果:
- 在三名AVM患者中发现了新的体质RIT1脱变异.
- 在体外,RIT1变异导致ERK1/2信号的过度激活.
- 在斑马鱼中RIT1变异的过度表达诱导了AVM形成.
- 抑制MEK抑制了ERK1/2过活化和AVM的发展.
- 特拉美丁尼布治疗减少了患者的出血和AVM大小.
结论:
- 阴性RIT1变体与AVM的发病因子有关.
- RIT1调节RAS-MAPK信号,有助于血管的发展.
- 用像特拉美丁尼布这样的抑制剂准MEK是AVM的一个潜在的治疗策略.
相关概念视频
MAPK Signaling Cascades
5.4K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.4K
The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
Small GTPases - Ras and Rho
3.9K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
3.9K
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K


